Hortobagyi GN - Search Results

1

Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.

Jin Q, Yuan LX, Boulbes D, Baek JM, Wang YN, Gomez-Cabello D, Hawke DH, Yeung SC, Lee MH, Hortobagyi GN, Hung MC, Esteva FJ. Jin Q, et al. Among authors: hortobagyi gn. Breast Cancer Res. 2010;12(6):R96. doi: 10.1186/bcr2777. Epub 2010 Nov 16. Breast Cancer Res. 2010. PMID: 21080941 Free PMC article.

2

Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma.

Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M. Ro J, et al. Among authors: hortobagyi gn. Cancer Res. 1988 Jan 1;48(1):161-4. Cancer Res. 1988. PMID: 3334990

3

The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.

Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC. Chang JY, et al. Among authors: hortobagyi gn. Oncogene. 1997 Feb 6;14(5):561-8. doi: 10.1038/sj.onc.1200861. Oncogene. 1997. PMID: 9053854

4

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.

Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Yu D, et al. Among authors: hortobagyi gn. Oncogene. 1998 Apr 23;16(16):2087-94. doi: 10.1038/sj.onc.1201729. Oncogene. 1998. PMID: 9572489

5

Progress in endocrine therapy for breast carcinoma.

Hortobagyi GN. Hortobagyi GN. Cancer. 1998 Jul 1;83(1):1-6. doi: 10.1002/(sici)1097-0142(19980701)83:1<1::aid-cncr1>3.0.co;2-x. Cancer. 1998. PMID: 9655286 No abstract available.

6

Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.

Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC. Zhang L, et al. Among authors: hortobagyi gn. Oncogene. 1998 Jun 4;16(22):2855-63. doi: 10.1038/sj.onc.1201813. Oncogene. 1998. PMID: 9671406

7

A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer.

Hortobagyi GN, Hung MC, Lopez-Berestein G. Hortobagyi GN, et al. Hum Gene Ther. 1998 Aug 10;9(12):1775-98. doi: 10.1089/hum.1998.9.12-1775. Hum Gene Ther. 1998. PMID: 9721088 Clinical Trial. No abstract available.

8

Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.

Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Zhang L, et al. Among authors: hortobagyi gn. Clin Cancer Res. 1999 Feb;5(2):343-53. Clin Cancer Res. 1999. PMID: 10037184

9

Locally advanced breast cancer.

Esteva FJ, Hortobagyi GN. Esteva FJ, et al. Among authors: hortobagyi gn. Hematol Oncol Clin North Am. 1999 Apr;13(2):457-72, vii. doi: 10.1016/s0889-8588(05)70065-4. Hematol Oncol Clin North Am. 1999. PMID: 10363140 Review.

10

Recent developments in breast cancer therapy.

Hortobagyi GN, Hung MC, Buzdar AU. Hortobagyi GN, et al. Semin Oncol. 1999 Aug;26(4 Suppl 12):11-20. Semin Oncol. 1999. PMID: 10482190 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,102 results

Search Page